News Story: Full Text
Sponsored By
Cleveland Clinic Brain Tumor and Neuro-Oncology Center
Please Click On The Above Banner For More Details
Braintumor Website

 

xCures to Implement an Intermediate Size Expanded Access Protocol for ONC201 in H3 K27M-mutant Gliomas

Al's Comment:
This is an exciting experimental treatment for brain tumors with the H3K27M mutation.  This is usually found in children with DIPG, and people with midline gliomas - especially of the thalamus.  There are clinical trials open for it, but if you do not qualify for the trials, you may be able to get it outside of the trial.   There is no cost for the expanded access program because we - the Musella Foundation - along with the other organizations mentioned in the press release - funded it with a $1 million  grant!   Early results presented at the last Society of Neuro-oncology meeting looked good with a few impressive responses, which is rarely, if ever seen in tumors with this mutation.
 
Disclosure:  I have a small ownership interest in xCures.
 

 


Posted on: 03/12/2019

xCures to Implement an Intermediate Size Expanded Access Protocol for ONC201 in H3 K27M-mutant Gliomas

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740